Does psyllium lower cholesterol?

Yes, by a modest and consistent amount. In 28 randomized trials with 1924 people, a median of about 10.2 g of psyllium a day lowered LDL cholesterol by 13 mg/dL (95% CI 10 to 15; metric: 0.33 mmol/L, 0.27 to 0.38), on moderate certainty evidence. Three other meta-analyses land close by. No trial has yet tested whether psyllium prevents heart attacks or deaths.

Established. Psyllium lowers LDL cholesterol. The 28-trial meta-analysis graded the evidence moderate for LDL and non-HDL cholesterol, which fell by 15 mg/dL (0.39 mmol/L), and high for apolipoprotein B, which fell by 0.05 g/L. A 2024 analysis of 29 trials in 2769 adults found 0.35 mmol/L, and a 2009 analysis of 21 placebo-controlled trials found 0.278 mmol/L. HDL cholesterol and triglycerides did not change in the pooled analyses.

What the trials found

The 2009 meta-analysis pooled 1717 people with mildly to moderately raised cholesterol who took 3 to 20 g of psyllium a day for more than 2 weeks. Total cholesterol fell by 15 mg/dL (0.375 mmol/L) and LDL by 11 mg/dL (0.278 mmol/L), and larger doses lowered it more. An older pooling of 8 trials, in people already on a low-fat diet, found that 10.2 g a day lowered LDL by 7 percent and total cholesterol by 4 percent against placebo. Those trials reported percentages, while the chart above shows the pooled drops in mmol/L.

The longest single trial ran 26 weeks across several centers, in people whose LDL was still high after 8 weeks of a cholesterol-lowering diet. Taking 5.1 g twice a day left LDL 6.7 percent and total cholesterol 4.7 percent lower than placebo. The abstract does not say how many people took part.

Unsettled. How much the dose matters is not settled. The 2009 analysis found a significant dose response. The newest one, from 2025, pooled 41 trials with 2049 adults and found LDL lower by 8.55 mg/dL, with no significant linear effect of dose or duration and very large differences between trials (I2 88 percent). The two used different trial sets and cannot both be the final word.

Psyllium with a statin

A meta-analysis of 3 small trials in people already on statins found that adding psyllium lowered LDL about as much as doubling the statin dose. In one trial of 68 patients, some took 10 mg of simvastatin with placebo and some 10 mg with 15 g of psyllium a day. After 8 weeks LDL had fallen by 55 mg/dL (1.42 mmol/L) on placebo and by 63 mg/dL (1.63 mmol/L) with psyllium. That is a reason to talk to your doctor, and not a reason to change a prescribed dose yourself.

Children and teenagers

In an 8-week trial of 51 Brazilian children and teenagers aged 6 to 19 with raised cholesterol, already on a cholesterol-lowering diet, 7 g of psyllium a day lowered LDL by 10.7 percent, which was 14 mg/dL (0.36 mmol/L). It is one small trial.

Who should be careful

Not for everyone. Psyllium swells with water, and taken dry or with too little fluid it can block the throat. US federal rules for these products warn that obstruction of the esophagus and choking are significant risks when they are taken without enough fluid, or by people with a narrowed esophagus or difficulty swallowing. A case report describes a 26-year-old man on an extreme slimming regimen whose bowel became blocked after psyllium-containing diet food.

In one crossover trial of 68 adults taking 15 g a day for 30 days, triglycerides fell 17 percent in the 24 men and rose 16 percent in the 21 postmenopausal women, while LDL fell by 7 to 9 percent. That sex difference comes from a single trial and the pooled analyses found no overall effect on triglycerides.

Psyllium can cause allergy, rarely and seriously. A 60-year-old nurse who had only ever handled psyllium laxatives at work had an anaphylactic reaction the first time she ate a psyllium cereal. That is one case, and it shows that people who breathe in the powder can become sensitized.

In the constipation trials, side effects were minor. In one small trial 2 people on psyllium (18 percent) had abdominal pain against none on control. In 30 elderly inpatients on digoxin, 4 weeks of an ispaghula laxative, which is psyllium, did not change blood digoxin levels. That trial is small and from 1987, and it says nothing about other medicines. We found no card on spacing psyllium from other tablets.

What expert bodies say

The US and the EU read the same evidence and came to different labels. The FDA lets foods claim a lower risk of heart disease when they are part of a diet with 7 g or more a day of soluble fiber from psyllium seed husk. The EU did not authorize a general claim that soluble fiber from oat, psyllium, pectin or guar gum lowers blood cholesterol. A non-authorized claim means the dossier did not meet EU criteria when it was assessed. It is not a finding that psyllium has no effect.

How we searched

What would change this answer

• A trial of psyllium on heart attacks, strokes or deaths. We found none. The 7 percent lower risk of cardiovascular events in the 2024 analysis is an estimate modeled from the LDL change, not something anyone measured.
• A clear dose answer. One analysis found more psyllium lowers LDL more, the newest found no linear dose effect. A trial comparing doses directly would tell people whether 7 g is enough or 10 g is needed.
• A larger trial in postmenopausal women that tracks triglycerides, to test the single result that they rose.
• We did not search the trial registry for psyllium, so running trials may exist that this page does not know about.

Nutrition values and other findings for psyllium itself are on the psyllium husk page, and its evidence for constipation is in our review of whether psyllium helps constipation.

Sources

1. ev-psychol-01 · Meta-analysis or systematic review · systematic review and meta-analysis of RCTs · n = 1924
   Supplementation of a median dose of ∼10.2 g psyllium significantly reduced LDL cholesterol (MD = -0.33 mmol/L; 95% CI: -0.38, -0.27 mmol/L; P < 0.00001), non-HDL cholesterol (MD = -0.39 mmol/L; 95% CI: -0.50, -0.27 mmol/L; P < 0.00001), and apoB (MD = -0.05 g/L; 95% CI: -0.08, -0.03 g/L; P < 0.0001).
   
   Who: individuals with or without hypercholesterolemia in randomized controlled trials of at least 3 weeks
   Effect: LDL MD -13 mg/dL (95% CI -15 to -10; metric: -0.33 mmol/L, -0.38 to -0.27); non-HDL MD -15 mg/dL (-19 to -10; metric: -0.39 mmol/L, -0.50 to -0.27); apoB MD -0.05 g/L (-0.08 to -0.03); median dose about 10.2 g/day
   Certainty: GRADE moderate for LDL and non-HDL (downgraded for inconsistency), high for apoB.
   Am J Clin Nutr, 2018 · checked 2026-10-06 · we read the abstract
2. ev-psychol-02 · Meta-analysis or systematic review · systematic review and meta-analysis of RCTs · n = 2769
   Compared with the control group, Plantago consumption significantly reduced total cholesterol (TC) by 0.28 mmol/L and low-density lipoprotein cholesterol (LDL-C) by 0.35 mmol/L, correlating to an estimated 7% decrease in cardiovascular event risk.
   
   Who: adults in randomized controlled trials of Plantago (psyllium) consumption
   Effect: TC -0.28 mmol/L; LDL-C -14 mg/dL (-0.35 mmol/L); estimated 7% lower cardiovascular event risk (modeled, not observed); no substantial effect on HDL or triglycerides
   Certainty: The 7% event figure is an estimate from LDL change, not a measured outcome; the abstract omits confidence intervals.
   Nutr Res, 2024 · checked 2026-10-06 · we read the abstract
3. ev-psychol-03 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of RCTs · n = 2049
   In this study, 41 Randomized Controlled Trials articles and 2049 participants were included.
   
   Who: adults in randomized controlled trials of psyllium supplementation
   Effect: LDL WMD -8.55 mg/dL (95% CI -12.92 to -4.19; I2 88%); total cholesterol WMD -9.05 mg/dL (-13.71 to -4.40); HDL and triglycerides not significant; no significant linear dose or duration effect
   Certainty: Newest synthesis (2025), outside the local corpus snapshot; abstract only; considerable heterogeneity.
   Genes Nutr, 2025: Psyllium supplementation and lipid profiles: systematic review and dose-response meta-analysis of randomized controlled trials · checked 2026-10-06 · we read the abstract
4. ev-psychol-04 · Meta-analysis or systematic review · meta-analysis of randomized placebo-controlled trials · n = 1717
   RESULTS: Compared with placebo, consumption of psyllium lowered serum total cholesterol by 0.375 mmol/l (95% CI: 0.257-0.494 mmol/l), and LDL cholesterol by 0.278 mmol/l (95% CI: 0.213-0.312 mmol/l).
   
   Who: subjects with mild-to-moderate hypercholesterolemia; 1030 on psyllium and 687 on placebo; 3.0 to 20.4 g per day for more than 2 weeks
   Effect: total cholesterol -15 mg/dL (95% CI 9.9 to 19; metric: -0.375 mmol/L, 0.257 to 0.494); LDL -11 mg/dL (8.2 to 12; metric: -0.278 mmol/L, 0.213 to 0.312); significant dose-response
   Certainty: Older synthesis (2009); open-label and blinded trials pooled.
   Eur J Clin Nutr, 2009 · checked 2026-10-06 · we read the abstract
5. ev-psychol-05 · Meta-analysis or systematic review · meta-analysis of controlled trials · n = 656
   RESULTS: Consumption of 10.2 g psyllium/d lowered serum total cholesterol by 4% (P < 0.0001), LDL cholesterol by 7% (P < 0.0001), and the ratio of apolipoprotein (apo) B to apo A-I by 6% (P < 0.05) relative to placebo in subjects already consuming a low-fat diet, with no effect on serum HDL or triacylglycerol concentrations.
   
   Who: men and women with mild-to-moderate hypercholesterolemia already on a low-fat diet; 384 on psyllium, 272 on cellulose placebo
   Effect: total cholesterol -4%, LDL -7%, apoB/apoA-I ratio -6% vs placebo; no effect on HDL or triacylglycerol; safety pooled from 19 studies of 6 weeks to 6 months
   Certainty: Industry-era trials (2000); 8 trials of a single dose.
   Am J Clin Nutr, 2000 · checked 2026-10-06 · we read the abstract
6. ev-psychol-06 · Meta-analysis or systematic review · systematic review and meta-analysis of RCTs · n = —
   Adding psyllium fiber resulted in reductions in low-density lipoprotein-cholesterol equivalent to doubling the statin dose.
   
   Who: subjects already receiving statins in randomized controlled trials of 4 to 12 weeks
   Effect: LDL reduction with psyllium plus statin equivalent to doubling the statin dose (p = 0.001 vs statin alone)
   Certainty: Only 3 small trials; the abstract gives no pooled LDL number.
   Am J Cardiol, 2018 · checked 2026-10-06 · we read the abstract
7. ev-psychol-07 · Randomized controlled trial(s) · randomized blinded placebo-controlled trial · n = 68
   All treatments were well tolerated, and after 8 weeks the mean LDL-C levels in the group receiving 10 mg of simvastatin plus placebo fell by 55 mg/dL (1.42 mmol/L) from baseline, compared with 63 mg/dL (1.63 mmol/L) in the group receiving 10 mg of simvastatin plus psyllium (P = .03).
   
   Who: 68 patients randomized to simvastatin 20 mg plus placebo, 10 mg plus placebo, or 10 mg plus 15 g psyllium (Metamucil) daily
   Effect: LDL -63 mg/dL (1.63 mmol/L) with 10 mg simvastatin plus psyllium vs -55 mg/dL (1.42 mmol/L) with 10 mg plus placebo at 8 weeks (P = .03)
   Certainty: Small trial; 8-week lipid endpoint.
   Arch Intern Med, 2005 · checked 2026-10-06 · we read the abstract
8. ev-psychol-08 · Randomized controlled trial(s) · randomized placebo-controlled multicentre trial · n = —
   RESULTS: Serum total and LDL-cholesterol concentrations were 4.7% and 6.7% lower in the psyllium group than in the placebo group after 24-26 wk (P < 0.001).
   
   Who: men and women with primary hypercholesterolemia, LDL 130 to 190 mg/dL (3.36 to 4.91 mmol/L) after 8 weeks of AHA Step I diet
   Effect: total cholesterol -4.7%, LDL -6.7% vs placebo after 24 to 26 weeks (P < 0.001)
   Certainty: The abstract does not give the number randomized.
   Am J Clin Nutr, 2000 · checked 2026-10-06 · we read the abstract
9. ev-psychol-09 · Randomized controlled trial(s) · randomized, double-blind, placebo-controlled, parallel trial · n = 51
   Statistically significant changes between the control and intervention groups over time were observed for total cholesterol (7·7%; - 0·39 mmol/l; P= 0·003) and LDL-C (10·7%; - 0·36 mmol/l; P= 0·01).
   
   Who: fifty-one Brazilian children and adolescents aged 6 to 19 years with mild-to-moderate hypercholesterolemia, after 6 weeks of NCEP Step 2 diet
   Effect: total cholesterol -7.7% (-15 mg/dL (-0.39 mmol/L); P=0.003); LDL -10.7% (-14 mg/dL (-0.36 mmol/L); P=0.01); no serious adverse effects
   Certainty: Small single trial.
   Br J Nutr, 2015 · checked 2026-10-06 · we read the abstract
10. ev-psychol-10 · Randomized controlled trial(s) · randomized crossover trial · n = 68
    Psyllium supplementation significantly lowered plasma triacylglycerol concentrations in men by 17% and raised triacylglycerol concentrations in postmenopausal women by 16% (P < 0.01).
    
    Who: 24 men, 23 premenopausal women and 21 postmenopausal women in a randomized crossover trial
    Effect: LDL -7 to -9% (P < 0.0001); triglycerides -17% in men, +16% in postmenopausal women (P < 0.01)
    Certainty: 30-day periods; sex difference is from one trial.
    Am J Clin Nutr, 2001 · checked 2026-10-06 · we read the abstract
11. ev-psychol-11 · Position of an expert body · federal regulation · n = —
    Esophageal obstruction and asphyxiation due to orally-administered drug products containing water-soluble gums, hydrophilic gums, and hydrophilic mucilloids as active ingredients are significant health risks when these products are taken without adequate fluid or when they are used by individuals with esophageal narrowing or dysfunction, or with difficulty in swallowing.
    
    Who: users of oral water-soluble gum products such as psyllium in dry form
    Effect: —
    Certainty: Applies to OTC drug labeling; the same physical risk applies to dry psyllium powders sold as food.
    21 CFR 201.319, Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids as active ingredients; required warnings and directions · checked 2026-10-06 · we read the section
12. ev-psychol-12 · Position of an expert body · federal regulation · n = —
    7 g or more per day of soluble fiber from psyllium seed husk.
    
    Who: US food labeling rule
    Effect: health claim threshold 7 g/day soluble fiber from psyllium seed husk
    Certainty: Authorized health claim (21 CFR 101.81), not a treatment recommendation.
    21 CFR 101.81, Health claims: Soluble fiber from certain foods and risk of coronary heart disease · checked 2026-10-06 · we read the section
13. ev-psychol-13 · Position of an expert body · EU Register on nutrition and health claims, claim POL-HC-7950, snapshot of 2026-09-21 · n = —
    POL-HC-7950 Soluble Fibre (from oat, psyllium, pectin or guar gum) Inclusion of this fibre in a healthy diet and lifestyle can lead to serum cholesterol reduction. Non-authorised
    
    Who: EU food labeling
    Effect: claim non-authorized
    Certainty: Non-authorized means the dossier did not meet EU criteria at assessment, not that there is no effect.
    EU Register on nutrition and health claims, POL-HC-7950 · checked 2026-10-06 · we read the dataset
14. ev-psy-04 · Meta-analysis or systematic review · systematic review and meta-analysis of randomized controlled trials, adverse events narrative · n = —
    One study administering psyllium reported that 2 participants (18%) in the intervention group had abdominal pain, compared to none in the control group (28).
    
    Who: Psyllium trials within a meta-analysis of fiber in chronic constipation
    Effect: abdominal pain 18% vs 0% in one small trial; no serious adverse events in two psyllium trials
    Certainty: Adverse events were reported inconsistently and not pooled.
    Am J Clin Nutr, 2022 · checked 2026-10-06 · we read the fulltext
15. ev-psy-11 · Randomized controlled trial(s) · randomized comparative trial, 4 weeks · n = 30
    Ispaghula had no influence at any time. It is concluded that neither wheat bran nor the ispaghula formulation has any clinically relevant influence on therapeutic digoxin levels in geriatric patients.
    
    Who: 30 geriatric in-patients on digoxin, 14 on ispaghula, 16 on wheat bran
    Effect: no influence of ispaghula on steady-state digoxin at 2 or 4 weeks
    Certainty: Small and old (1987); one drug only. Says nothing about other narrow-margin drugs.
    Drug Nutr Interact, 1987 · checked 2026-10-06 · we read the abstract
16. ev-psy-12 · Laboratory or animal data · case series · n = 1
    We report a case of a 60-year-old woman with no prior history of psyllium ingestion who developed anaphylactic symptoms after eating a psyllium-containing cereal. Her only previous exposure was dispensing a psyllium-containing laxative as a nurse.
    
    Who: One 60-year-old woman, previous exposure only by dispensing psyllium laxative
    Effect: IgE-mediated anaphylaxis confirmed by skin test and basophil histamine release
    Certainty: Single case. Shows sensitization by inhalation in people who handle the powder.
    JAMA, 1990 · checked 2026-10-06 · we read the abstract
17. ev-psy-13 · Laboratory or animal data · case series · n = 1
    Since patients undergoing extreme slimming regimens may cause intestinal obstruction if psyllium is taken without adequate fluid intake caution should be taken when eating psyllium.
    
    Who: One 26-year-old man on an extreme slimming regimen
    Effect: intestinal obstruction
    Certainty: Single case report.
    Acute Med Surg, 2023 · checked 2026-10-06 · we read the abstract